The importance of HPV testing in oropharyngeal cancer in two US populations.
Study reveals significant gaps in HPV testing for throat cancer across US populations, identifying where risk stratification and treatment eligibility assessment falls short.
Lawas et al. compared HPV testing rates and positivity in oropharyngeal squamous cell carcinoma across two distinct US population cohorts, identifying significant geographic and demographic variation that affects prognostic risk stratification and treatment eligibility. The study reinforces the clinical necessity of HPV status determination in all oropharyngeal cancers and identifies populations with testing gaps that undermine precision risk stratification and treatment deescalation eligibility.
What the study was
- Study design
- Retrospective cohort study (two US population cohorts)
- Population
- Oropharyngeal squamous cell carcinoma patients across two distinct US populations
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Neoplasia
Why it surfaced
Multi-cohort study validating HPV testing importance for precision stratification in oropharyngeal cancer in Neoplasia; relevant to T5 precision oncology and population-level biomarker adoption.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.